HC-030031

HC-030031
Identifiers
	IUPAC name 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)-N-(4-propan-2-ylphenyl)acetamide;
CAS Number	349085-38-7 ;
PubChem CID	1150897;
ChemSpider	976407;
UNII	MU78VFH9C7;
ChEMBL	ChEMBL1086310;
CompTox Dashboard (EPA)	DTXSID10360763 ;
ECHA InfoCard	100.159.785
Chemical and physical data
Formula	C18H21N5O3
Molar mass	355.398 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C1=CC=C(C=C1)NC(=O)CN2C=NC3=C2C(=O)N(C(=O)N3C)C;
	InChI InChI=1S/C18H21N5O3/c1-11(2)12-5-7-13(8-6-12)20-14(24)9-23-10-19-16-15(23)17(25)22(4)18(26)21(16)3/h5-8,10-11H,9H2,1-4H3,(H,20,24); Key:HEQDZPHDVAOBLN-UHFFFAOYSA-N;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

HC-030031 is a drug which acts as a potent and selective antagonist for the TRPA1 receptor, and has analgesic and antiinflammatory effects.^[1]^[2]^[3]^[4]

References

^ Eid SR, Crown ED, Moore EL, Liang HA, Choong KC, Dima S, et al. (October 2008). "HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity". Molecular Pain. 4: 1744-8069–4-48. doi:10.1186/1744-8069-4-48. PMC 2584039. PMID 18954467.
^ Pereira LM, Lima-Júnior RC, Bem AX, Teixeira CG, Grassi LS, Medeiros RP, et al. (February 2013). "Blockade of TRPA1 with HC-030031 attenuates visceral nociception by a mechanism independent of inflammatory resident cells, nitric oxide and the opioid system". European Journal of Pain. 17 (2): 223–33. doi:10.1002/j.1532-2149.2012.00177.x. PMID 22689151. S2CID 9421113.
^ Koivisto A, Chapman H, Jalava N, Korjamo T, Saarnilehto M, Lindstedt K, Pertovaara A (January 2014). "TRPA1: a transducer and amplifier of pain and inflammation". Basic & Clinical Pharmacology & Toxicology. 114 (1): 50–5. doi:10.1111/bcpt.12138. PMID 24102997.
^ Achanta S, Chintagari NR, Brackmann M, Balakrishna S, Jordt SE (September 2018). "TRPA1 and CGRP antagonists counteract vesicant-induced skin injury and inflammation". Toxicology Letters. 293: 140–148. doi:10.1016/j.toxlet.2018.03.007. PMC 5975083. PMID 29535050.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Eid SR, Crown ED, Moore EL, Liang HA, Choong KC, Dima S, et al. (October 2008). "HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity". Molecular Pain. 4: 1744-8069–4-48. doi:10.1186/1744-8069-4-48. PMC 2584039. PMID 18954467.

[2] Pereira LM, Lima-Júnior RC, Bem AX, Teixeira CG, Grassi LS, Medeiros RP, et al. (February 2013). "Blockade of TRPA1 with HC-030031 attenuates visceral nociception by a mechanism independent of inflammatory resident cells, nitric oxide and the opioid system". European Journal of Pain. 17 (2): 223–33. doi:10.1002/j.1532-2149.2012.00177.x. PMID 22689151. S2CID 9421113.

[3] Koivisto A, Chapman H, Jalava N, Korjamo T, Saarnilehto M, Lindstedt K, Pertovaara A (January 2014). "TRPA1: a transducer and amplifier of pain and inflammation". Basic & Clinical Pharmacology & Toxicology. 114 (1): 50–5. doi:10.1111/bcpt.12138. PMID 24102997.

[4] Achanta S, Chintagari NR, Brackmann M, Balakrishna S, Jordt SE (September 2018). "TRPA1 and CGRP antagonists counteract vesicant-induced skin injury and inflammation". Toxicology Letters. 293: 140–148. doi:10.1016/j.toxlet.2018.03.007. PMC 5975083. PMID 29535050.

[1]